Document Detail


Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.
MedLine Citation:
PMID:  22212569     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Effective management of adverse events (AEs) is important to prevent treatment discontinuation and optimize hepatitis C virus infection eradication rates. The addition of direct-acting antiviral agents, telaprevir (TVR) or boceprevir to pegylated interferon (PEG-IFN) and ribavirin (RBV) represents a new era of therapy associated with an improvement in treatment response rates and an impairment of the safety profile compared to PEG-IFN/RBV. An increase in the frequency and severity of anaemia was reported in clinical trials for both drugs, and skin disorders including rash and pruritus occurred more frequently with the TVR-based regimen. These AEs are generally manageable and do not lead to early discontinuation. The management of anaemia has not been clearly established, and the impact of RBV dose reductions and erythropoietin alpha use on treatment efficacy and safety must be clarified. The management of rashes, which were mild and moderate in more than 90% of the cases, is well planned, does not require TVR discontinuation and can be treated using emollients and topical corticosteroids. However, approximately 5% of rashes were severe, and a few cases were classified as severe cutaneous adverse reactions leading to treatment discontinuation.
Authors:
Christophe Hézode
Related Documents :
23734489 - Cessation of a salmon decline with control of parasites.
21311079 - A review of neuroendoscopy and potential applications in veterinary medicine.
12108219 - Character impact odorants of the apple cultivars elstar and cox orange.
21710189 - A retrospective assessment comparing pharmacist-managed anticoagulation clinic with phy...
21874059 - The effect of oral management on the severity of oral mucositis during hematopoietic sct.
24450929 - Selective alternate derivatization of the hexaphenylbenzene framework through a thermod...
17170689 - Evaluation of biatain soft-hold foam dressing.
22858599 - The endovascular management of a neurofibromatosis vasculopathy: a case report.
24182429 - Rebuilding the us beef herd: rethinking the way industry develops replacements.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  32 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  32-8     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
Affiliation:
Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France; INSERM U955, Créteil, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Next Document:  Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprev...